Several studies highlight the challenges inherent to using prenatal samples for methylation analysis. Therefore, we do not recommend using MS-MLPA probemixes on prenatal samples. Read more.
MRC Holland's Melt Assay for SMA screening in newborns addresses the need for easy‑to‑adopt first‑tier screening technologies as more countries move toward implementing national newborn screening programs. Read more.
A recent publication by MRC Holland researchers contributes valuable insights into the evolving field of newborn screening (NBS). Read more.
Our product packaging will receive updates which simplify processing and pave the way for future innovations – there are no changes to the product contents.
D007 Acute Lymphoblastic Leukemia was recognized as a valuable tool for enhanced molecular testing of pediatric acute lympoblastic leukemia (pALL) in a recent research article. Read more.
We have launched NXtec D024 KaryoProfiler, our newest digitalMLPA™ assay designed for comprehensive molecular karyotyping across a wide range of applications. Read more.
Introducing NXtec Hereditary Cancer Panel 2 – a broad panel for the detection of CNVs in cancer-associated genes and the presence of selected variants.
P242 Pancreatitis just received a major update, with the recently released D1 version featuring nine new target probes and three new mutation-specific probes, as well as three replaced target probes and eight replaced reference probes. The updated probe content facilitates enhanced detection of HP-related genetic alterations and improves assay robustness.
Terence Diane Fabella, a PhD candidate and MRC Holland researcher, will present her work on the development of digitalMLPA assays for newborn screening at three international conferences later this year.
Effective from 1 January 2026, we will be implementing a price increase of 3.6% on average on most of our products.
Join our mailing list to receive the latest information about our products, technologies and website.